EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Pre-Launch

ANDAORALTABLET, EXTENDED RELEASE

Lifecycle

Pre-Launch

Data completeness

1/8 — Limited

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE by Cipla is contain: empagliflozin, a sglt2 inhibitor, and metformin hcl, a biguanide.

Drug data last refreshed Yesterday

Mechanism of Action

contain: empagliflozin, a SGLT2 inhibitor, and metformin HCl, a biguanide. Empagliflozin Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin reduces…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Worked on EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE at Cipla? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.